Continuous cardiac monitoring in a patient with terminal pulmonary hypertension and eventual bilateral lung transplantation

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 538 KB, PDF-dokument

As pulmonary arterial hypertension (PAH) progress, arrhythmias are becoming an increasingly prominent phenomenon. Supraventricular tachycardias have been shown to have an incidence of up to 35% in pulmonary hypertension. Continuous cardiac monitoring was deployed in a patient with severe PAH 100 days before bilateral lung transplantation (BLTX). Despite being graded as WHO functional class IV, no arrhythmias were observed before BLTX. Furthermore, the case describes clinical improvement, along with a significant increase in heart rate variability (HRV) and decrease in night-time heart rate in the post-transplantation period. No arrhythmias were observed preoperatively during continuous monitoring in a 100-day period despite the patient's intrinsically high risk for arrhythmias. Increasing HRV and lower resting heart rate were observed after BLTX. Since these parameters correlate with the clinical condition, they might be valuable in risk assessment in patients with pulmonary hypertension.

OriginalsprogEngelsk
Artikelnummere248304
TidsskriftBMJ Case Reports
Vol/bind15
Udgave nummer6
ISSN1757-790X
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
Competing interests SD is a part-time employee of Vital Beats, not related to this work. JHS is a member of an advisory board for Medtronic, has received research grant and speaker fee from Medtronic unrelated to this study and has received research grant from Gilead unrelated to this research project. JC is a member of an advisory board for Janssen, and the institution has received research grants and speaker fees. In the same way for United Therapeutics for clinical trials and Astra Zeneca and Ferrer for speaker fees.

Funding Information:
Funding The study was supported by an investigator initiated study research grant from Jansson Pharmaceuticals.

Publisher Copyright:
© BMJ Publishing Group Limited 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

ID: 323983544